News

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Ochre Bio, a pioneer in chronic liver disease medicine development, announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for…
Read More...

TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA…
Read More...

Evotec SE and Variant Bio, Inc. announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Fibrosis is characterised by marked and…
Read More...

Vertex Pharmaceuticals Incorporated announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and…
Read More...

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, exits from stealth following a $10m seed financing round. Outrun's platform has enabled it…
Read More...

IGM Biosciences, Inc. announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on…
Read More...

Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical…
Read More...

Clearmind Medicine Inc. announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant…
Read More...

Innate Pharma SA announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating…
Read More...

Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive…
Read More...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
Read More...

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of…
Read More...

Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher…
Read More...

Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd., a company developing treatments for amyotrophic…
Read More...

Starpharma announces it has entered into a strategic partnership with Medicxi, a leading life sciences investment firm dedicated to financing companies developing innovative medicines,…
Read More...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug…
Read More...